financetom
Business
financetom
/
Business
/
Tesla Reportedly Loses Spot as Europe's Top EV Seller to BYD
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tesla Reportedly Loses Spot as Europe's Top EV Seller to BYD
May 26, 2025 12:27 PM

08:47 AM EDT, 05/22/2025 (MT Newswires) -- Tesla's (TSLA) Europe sales in April were exceeded by Chinese competitor BYD for the first time, multiple media reports said Thursday, citing market researcher Jato Dynamics.

BYD electric vehicles sales in Europe rose 169% year-on-year to 7,231 units last month while Volkswagen EV sales rose 61% and Tesla registrations fell 49% to 7,165 units even as European EV sales grew 28%, the reports said.

Tesla remains the second largest EV seller in Europe, the reports said.

BYD this week also launched a new fully electric hatchback priced at under 23,000 euros ($26,009), news outlets reported.

Tesla did not immediately reply to MT Newswires' request for comment.

Shares were 1.5% lower in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Australia's Boral urges shareholders to reject Seven Group's $1.3 billion offer
Australia's Boral urges shareholders to reject Seven Group's $1.3 billion offer
Mar 19, 2024
(Reuters) -Australia's Boral on Tuesday recommended investors reject its largest shareholder Seven Group Holdings' A$1.9 billion ($1.25 billion) offer for the company claiming it undervalues the building products group. Seven Group, controlled by billionaire Kerry Stokes and his family, already owns nearly 72% of Boral and had launched a bid last month to acquire full control of Boral. The proposal...
AstraZeneca to buy Fusion Pharma for $2 billion in cash
AstraZeneca to buy Fusion Pharma for $2 billion in cash
Mar 19, 2024
March 19 (Reuters) - AstraZeneca ( AZN ) said on Tuesday it has agreed to buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc ( FUSN ) for about $2 billion in cash. The drugmaker will pay $21 per Fusion share plus a non-transferable contingent value right of $3 per share. ...
Thyssenkrupp starts due diligence phase on marine unit deal with Carlyle
Thyssenkrupp starts due diligence phase on marine unit deal with Carlyle
Mar 19, 2024
March 19 (Reuters) - Thyssenkrupp on Tuesday said it has entered a due diligence phase on the sale of its marine unit with investment firm Carlyle. At the same time, talks are being held with the German government on the state's participation in thyssenkrupp's marine business, the industrial conglomerate added. ...
BRIEF-Fusion Pharmaceuticals To Be Acquired By Astrazeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer
BRIEF-Fusion Pharmaceuticals To Be Acquired By Astrazeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer
Mar 19, 2024
March 19 (Reuters) - Fusion Pharmaceuticals Inc ( FUSN ) : * FUSION PHARMACEUTICALS TO BE ACQUIRED BY ASTRAZENECA, ACCELERATING DEVELOPMENT OF NEXT-GENERATION RADIOCONJUGATES TO TREAT CANCER * REPRESENTING A TOTAL TRANSACTION VALUE OF APPROXIMATELY $2.4 BILLION INCLUDING CVR * SHAREHOLDERS TO RECEIVE $21.00 PER SHARE IN CASH AT CLOSING PLUS A NON-TRANSFERRABLE CVR OF $3.00 PER SHARE * UPFRONT...
Copyright 2023-2026 - www.financetom.com All Rights Reserved